We are live on ! Find out more
CURX

Curanex Pharmaceuticals
CURX

8 hedge funds and large institutions have $168K invested in Curanex Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more capital invested

Capital invested by funds: $140K → $168K (+$27.1K)

0.02% less ownership

Funds ownership: 0.08% → 0.06% (-0.02%)

27% less funds holding

Funds holding: 11 → 8 (-3)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
8
Holders Change
-3
Holders Change %
-27.27%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$34.7K
2
TSS
Two Sigma Securities
New York
+$21.3K
3
Citigroup
Citigroup
New York
+$7.26K
4
XT
XTX Topco
Cayman Islands
+$3.34K

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$23.7K
2
Citadel Advisors
Citadel Advisors
Florida
-$20.2K
3
Renaissance Technologies
Renaissance Technologies
New York
-$19.6K
4
Two Sigma Investments
Two Sigma Investments
New York
-$15.3K
5
Jane Street
Jane Street
New York
-$8.26K

CURX Hedge Fund Activity: Q1 2026 in Review

8 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q1 2026, worth a combined $168K — up 19% from $140K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CURX and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $34.7K. The largest seller was DRW Securities, exiting entirely with an estimated $23.7K sold.

  • 8 institutional investors held Curanex Pharmaceuticals (CURX) as of Q1 2026, down from 11 in Q4 2025.
  • Funds reported $168K of Curanex Pharmaceuticals stock for Q1 2026, up 19% quarter-over-quarter.
  • 2 funds opened new Curanex Pharmaceuticals positions in Q1 2026 and 5 closed out, a net change of -3 holders.
  • The largest Curanex Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $34.7K added.
  • The largest Curanex Pharmaceuticals seller in Q1 2026 was DRW Securities, an estimated $23.7K sold.

Based on aggregated 13F filings for Q1 2026.